Strategic Focus Target CNS indications with validated delivery technologies and patented SNAC assets to pursue prescription treatments, presenting a cross-sell opportunity to pharma partners seeking advanced CNS solutions.

Asset Transfer Recent asset sale of SNAC-related patent portfolio to Spoke Sciences may create licensing or collaboration opportunities to re-acquire or co-develop promising non-water-soluble ingredient delivery tech.

Phase Market Fit Limited scale operations (11-50 employees) and revenue in the sub-10M range suggest agility; approach lean teams with high-impact, plug-and-play CNS formulation partnerships that leverage existing approved delivery platforms.

Technology Leverage Use of established web technologies and FDA-approved delivery methods indicates compatibility with partners prioritizing compliance-ready, scalable manufacturing and rapid tech-transfer in cannabinoid or lipophilic drug programs.

Growth Signals Focused areas like anxiety and agitation in autism highlight niche but meaningful market segments; align with specialty pharma and contract development/manufacturing organizations seeking differentiated CNS offerings.